Last updated: September 20, 2026
Poloxamer 182 is a nonionic triblock copolymer excipient used primarily as a surfactant, emulsifier, solubilizer, wetting agent, and stabilizer. Its commercial profile is tied to pharmaceutical formulations, cosmetics, medical products, and industrial applications rather than to a standalone branded drug market. Public sources do not disclose audited global revenue for poloxamer 182 as a separate product category. The financial trajectory is therefore best assessed through formulation demand, supplier capacity, regulatory acceptance, raw-material costs, and substitution risk.
What is poloxamer 182 and how is it used?
Poloxamer 182 is a polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer. It is identified by CAS Registry Number 9003-11-6, although that CAS number covers a range of poloxamer compositions rather than a single narrowly defined molecular species.
Poloxamer 182 is generally associated with a lower hydrophilic-lipophilic balance than poloxamer 188 and poloxamer 407. The lower hydrophilicity can support emulsification, wetting, and solubilization of compounds that require a more lipophilic surfactant environment.
Typical functions include:
| Function |
Formulation role |
| Surfactant |
Reduces interfacial tension between active ingredients, water, oils, and excipient phases |
| Emulsifier |
Supports oil-in-water or water-in-oil systems |
| Wetting agent |
Improves dispersion of poorly wettable powders |
| Solubilizer |
Increases apparent solubility of selected hydrophobic compounds |
| Stabilizer |
Reduces aggregation or phase separation |
| Processing aid |
Improves powder handling, dispersion, and manufacturing consistency |
The suitability of poloxamer 182 depends on molecular-weight distribution, ethylene oxide and propylene oxide content, hydroxyl value, cloud point, peroxide content, water content, and residual impurities. Pharmaceutical buyers normally qualify the exact grade rather than purchasing solely on the generic name.
Which pharmaceutical formulations use poloxamer 182?
Poloxamer 182 can be used in oral, topical, ophthalmic, parenteral, and device-related formulations, but its practical use is formulation-specific. The strongest opportunities are generally in products requiring surfactant behavior without ionic charge.
Oral and solid-dose products
In oral formulations, poloxamer 182 may support wetting and dispersion of poorly soluble active pharmaceutical ingredients. Potential applications include:
- Immediate-release tablets and capsules
- Solid dispersions
- Amorphous dispersions
- Granules and powders
- Oral suspensions
- Lipid-based delivery systems
Its value is highest when small amounts improve dissolution or content uniformity. Formulators may compare it with poloxamer 188, poloxamer 407, sodium lauryl sulfate, polysorbates, and vitamin E polyethylene glycol succinate.
Topical and dermatological products
Poloxamer 182 can be used in creams, gels, lotions, and cleansing systems. Its nonionic character can help maintain compatibility with preservatives, active ingredients, and other surfactants. It may also be used in temperature-sensitive gel systems, although poloxamer 407 is more commonly associated with thermoresponsive pharmaceutical gels.
Parenteral and biologic formulations
The greatest commercial value in parenteral products often rests with poloxamer 188 rather than poloxamer 182. Poloxamer 182 may be considered where its lower hydrophilicity, surface activity, or interfacial behavior is advantageous. For biologics, developers evaluate surfactant-induced aggregation, oxidation, immunogenicity risk, extractables, and compatibility with filling systems.
The product-specific qualification burden is high. A formulation change involving poloxamer 182 can require new stability, container-closure, particulate, extractables, and toxicological assessments.
Medical devices and drug-device combinations
Poloxamer 182 may be used as a wetting or lubricating component in medical products and delivery systems. Device applications can generate demand outside the conventional pharmaceutical-excipient market, although regulatory requirements vary by device classification and intended use.
What is the FDA regulatory status of poloxamer 182?
Poloxamer 182 is an established excipient rather than a new chemical entity. Its regulatory status depends on the route of administration, grade, concentration, impurity profile, and specific use in a finished product.
The FDA Inactive Ingredient Database is the principal public reference for assessing historical use of excipients in approved drug products. An IID listing does not create blanket approval for every route, concentration, or formulation. It indicates prior use in approved products and can support regulatory justification when the proposed use is within relevant precedent.[1]
Key regulatory considerations include:
- The precise compendial or supplier specification.
- Route-specific precedent in the FDA IID.
- Maximum historical concentration for the intended dosage form.
- Residual solvents and degradation products.
- Peroxide and aldehyde levels.
- Elemental impurities.
- Microbial quality where applicable.
- Extractables and leachables for contact with packaging or devices.
- Compatibility with active ingredients and preservatives.
Poloxamer 182 should not be treated as interchangeable with poloxamer 188 or 407 solely because all three are poloxamers. Differences in hydrophilic-lipophilic balance, molecular-weight distribution, gel behavior, and impurity profile can alter product performance.
What pharmacopeial standards apply to poloxamer 182?
Pharmacopeial status depends on the specific monograph and market. The United States Pharmacopeia-National Formulary includes standards for poloxamer materials, but the applicable monograph must be matched to the designated poloxamer grade rather than inferred from a generic CAS number.[2]
European and other national pharmacopeias may use related but nonidentical naming, analytical methods, or acceptance criteria. Pharmaceutical buyers commonly require:
- Identification by infrared spectroscopy or equivalent testing
- Average molecular-weight controls
- Ethylene oxide and propylene oxide composition
- Hydroxyl value
- Water content
- Acidity or alkalinity
- Residue on ignition
- Peroxide value
- Heavy metals or elemental impurities
- Microbial limits
- Residual solvents
A supplier’s statement that a product is "pharmaceutical grade" does not by itself establish compliance with USP-NF, Ph. Eur., or other applicable standards.
Which companies supply poloxamer 182?
The commercial supply base includes large multinational chemical companies, excipient manufacturers, and regional distributors. Product names may differ by supplier and may refer to a grade family rather than an exact poloxamer 182 composition.
Relevant supplier groups include:
| Supplier group |
Commercial role |
| BASF |
Major supplier of pharmaceutical excipients and poloxamer products under Kolliphor and related brands |
| Croda |
Supplies specialty pharmaceutical excipients and surfactants, with product availability varying by grade and region |
| Regional excipient manufacturers |
Provide generic or customer-specific poloxamer grades |
| Distributors |
Offer local inventory, repackaging, regulatory documentation, and dual sourcing |
BASF’s Kolliphor portfolio is particularly relevant to poloxamer procurement, although the commonly marketed pharmaceutical products include poloxamer 188 and poloxamer 407 grades. Availability of a specific poloxamer 182 grade must be confirmed against the supplier’s current product documentation rather than assumed from the brand family.[3]
Commercial buyers usually assess:
- GMP manufacturing status
- DMF availability
- Change-control procedures
- Batch-to-batch molecular-weight consistency
- Supply continuity
- Regional manufacturing capacity
- Regulatory support
- Minimum order quantities
- Lead times
- Sterile or low-bioburden options
How large is the poloxamer 182 market?
No reliable public source separates poloxamer 182 revenue from the broader poloxamer, pharmaceutical surfactant, or specialty excipient markets. Commercial market reports typically aggregate several poloxamer grades and applications. Estimates differ because some reports include cosmetics and industrial uses while others cover pharmaceutical applications only.
The addressable market is best viewed as a niche within the broader pharmaceutical-excipient and specialty-surfactant sectors. Poloxamer 182 is unlikely to have the volume profile of poloxamer 188, which has extensive use in biologics, injectables, cell-culture processing, and protein stabilization.
Demand is driven by:
- Growth in poorly soluble drug candidates
- Increased use of amorphous solid dispersions
- Expansion of topical and complex delivery systems
- Outsourced formulation development
- Pharmaceutical manufacturing in Asia
- Demand for established excipients with regulatory histories
Demand is constrained by:
- Limited use of the exact 182 grade compared with other poloxamers
- Formulation-specific qualification requirements
- Availability of alternative surfactants
- Low excipient cost relative to the value of the finished drug
- Long customer-approval cycles
- Risk that a developer selects poloxamer 188 or 407 instead
What is the financial trajectory for poloxamer 182?
The likely financial trajectory is steady rather than high-growth. Revenue expansion depends less on price increases and more on new formulation wins, geographic penetration, and migration from laboratory development into commercial manufacturing.
Revenue drivers
A supplier can increase revenue through:
- Higher-volume commercial drug launches
- Long-term supply agreements
- Premium low-peroxide or low-bioburden grades
- Regional inventory and shorter lead times
- Custom specifications
- Regulatory documentation and technical support
- Dual-source qualification by major pharmaceutical companies
Margin drivers
Margins are affected by:
- Ethylene oxide and propylene oxide costs
- Energy and utilities
- Plant utilization
- Packaging and logistics
- Quality-control requirements
- Customer audit costs
- Batch size
- Inventory requirements
- Regional tariffs and currency movements
Poloxamer 182 is a relatively small cost component in most finished pharmaceutical products. That limits the ability to pass through large price increases unless the grade is technically difficult to replace or the supplier has strong regulatory qualification with the customer.
Financial downside risks
The main downside risks are substitution and demand concentration. A customer may replace poloxamer 182 with another surfactant after reformulation, especially during early development. Once the material is embedded in an approved product, replacement becomes more difficult because of regulatory and stability requirements.
The most defensible revenue is therefore linked to commercial products with established specifications and approved supply chains. Development-stage demand is less durable.
How does poloxamer 182 compare with poloxamer 188 and poloxamer 407?
| Attribute |
Poloxamer 182 |
Poloxamer 188 |
Poloxamer 407 |
| Relative hydrophilicity |
Lower |
Higher |
Very high |
| Common commercial role |
Emulsifier, wetting agent, surfactant |
Biologic stabilizer, surfactant, injectable excipient |
Solubilizer, gel former, topical and delivery systems |
| Thermoresponsive gel use |
Limited |
Limited |
Established |
| Biologic formulation relevance |
Selective |
High |
Selective |
| Replacement risk |
Moderate to high |
Moderate |
Moderate |
| Commercial visibility |
Lower |
High |
High |
| Typical buyer focus |
Surfactant performance and compatibility |
Protein stability, particulates, oxidation |
Gelation, viscosity, release profile |
Poloxamer 188 has stronger demand in biologics and parenteral formulations. Poloxamer 407 has a stronger position in topical and thermoresponsive delivery systems. Poloxamer 182 competes where its balance of hydrophobicity and surfactant activity improves formulation performance.
What patents protect poloxamer 182?
Poloxamer 182 itself is an established polymer and is not generally protected by a current composition-of-matter patent that would provide market exclusivity comparable to a pharmaceutical active ingredient. Patent risk is more likely to arise from:
- Drug formulations containing poloxamer 182
- Specific ratios of poloxamer 182 with an active ingredient
- Solid-dispersion manufacturing processes
- Lipid or polymeric delivery systems
- Topical or ophthalmic compositions
- Biologic stabilization methods
- Drug-device combinations
- Supplier-specific manufacturing or purification processes
A formulation patent may claim poloxamer 182 as one option among many excipients. That does not create exclusivity over the excipient itself. Patent analysis must therefore be conducted against the active ingredient, dosage form, concentration range, manufacturing process, and jurisdiction.
There is no standard Orange Book listing for poloxamer 182 as an excipient. Orange Book patents attach to approved drug products and their associated formulations or methods, not to the excipient as a standalone commercial substance.[4]
Are there Paragraph IV challenges involving poloxamer 182?
Paragraph IV litigation generally concerns patents listed for an approved drug product. Poloxamer 182 does not have an independent Orange Book exclusivity position, so Paragraph IV challenges would target a finished pharmaceutical product that uses the excipient, not poloxamer 182 itself.
Generic-entry risk depends on:
- Whether the drug product has listed formulation patents
- Whether the excipient concentration is claimed
- Whether the generic can design around the formulation
- Whether the reference product’s method-of-use patents remain enforceable
- Whether the ANDA applicant files a Paragraph IV certification
- Whether litigation triggers a 30-month stay under the Hatch-Waxman framework
For biologics, the relevant pathway is biosimilar or interchangeable-product competition. Poloxamer 182 could affect biosimilar comparability if it is present in the reference product, but excipient identity is only one part of the analytical and clinical assessment.[5]
What manufacturing and intellectual-property barriers affect supply?
Manufacturing barriers are technical and commercial rather than patent-based. Production requires controlled polymerization of ethylene oxide and propylene oxide blocks, followed by purification, drying, testing, and packaging.
Important supply-chain risks include:
- Feedstock availability
- Polymerization capacity
- Molecular-weight variability
- Residual monomer control
- Peroxide formation during storage
- Cross-contamination controls
- Site changes
- Regional logistics disruptions
- Limited availability of exact-grade alternatives
A pharmaceutical customer may spend months or years qualifying a second supplier. That switching cost can protect incumbent suppliers even when the underlying polymer is chemically unpatented.
What is the competitive outlook for poloxamer 182?
The outlook is stable but specialized. Growth should track complex formulation development rather than unit-volume expansion in conventional tablets. The strongest opportunities are in products where poloxamer 182 provides a measurable dissolution, dispersion, stability, or processing advantage and where the customer has already completed regulatory qualification.
Competitive pressure will remain high from poloxamer 188, poloxamer 407, polysorbates, sodium lauryl sulfate, PEG derivatives, lecithin, and proprietary surfactant systems. Suppliers with broad excipient portfolios, global GMP capacity, strong documentation, and reliable change control are better positioned than low-cost sellers competing only on price.
Key Takeaways
- Poloxamer 182 is a nonionic triblock copolymer excipient used for surfactant, wetting, emulsification, solubilization, and stabilization functions.
- Its market is a niche within broader pharmaceutical-excipient and specialty-surfactant categories.
- Public sources do not provide audited global revenue for poloxamer 182 as a separate product.
- The financial trajectory is likely steady, with growth tied to complex formulations and commercial product approvals.
- Poloxamer 188 and poloxamer 407 have broader commercial visibility in biologics, injectables, gels, and advanced delivery systems.
- The main competitive risks are substitution, customer qualification delays, and limited demand for the exact 182 grade.
- Poloxamer 182 has no standalone Orange Book exclusivity or conventional Paragraph IV exposure.
- Patent risk arises mainly from finished-drug formulations, delivery systems, manufacturing processes, and method-of-use claims.
- Supply-chain resilience, specification control, and regulatory documentation are more important barriers than composition-of-matter patents.
FAQs
Is poloxamer 182 the same as poloxamer 188?
No. Both are triblock copolymers, but they differ in composition, molecular-weight distribution, hydrophilic-lipophilic balance, and formulation performance. They should not be substituted without formulation and regulatory evaluation.
Is poloxamer 182 approved by the FDA?
Poloxamer materials have historical use in FDA-approved products, but approval is not blanket authorization for every route, concentration, grade, or formulation. The relevant FDA Inactive Ingredient Database entry and product-specific regulatory record must be evaluated.
Is poloxamer 182 suitable for injectable drugs?
It may be suitable in selected injectable formulations, but suitability depends on grade, impurity profile, concentration, route, toxicity assessment, and compatibility. Poloxamer 188 is more commonly associated with parenteral and biologic applications.
Does poloxamer 182 have a Drug Master File?
A supplier may maintain a Drug Master File or equivalent regulatory package for a specific grade. DMF availability is supplier-specific and should not be inferred from the generic excipient name.
Can poloxamer 182 be replaced without changing an approved drug product?
Usually not without assessment. A substitution can affect dissolution, stability, viscosity, particle formation, preservative performance, and bioavailability. The regulatory impact depends on the dosage form, change magnitude, and applicable post-approval-change framework.
References
- U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
- United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
- BASF. (n.d.). Kolliphor pharmaceutical excipients. https://pharma.basf.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
- U.S. Food and Drug Administration. (2024). Questions and answers on biosimilar development and the BPCI Act. FDA.
